Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for PTN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
March 31, 2026 0.1389M
December 31, 2025 18.02M
September 30, 2025 0.3282M
June 30, 2025 3.503M
March 31, 2025 4.458M
December 31, 2024 3.380M
September 30, 2024 -0.127M
June 30, 2024 5.991M
March 31, 2024 9.136M
December 31, 2023 4.974M
September 30, 2023 0.4489M
June 30, 2023 1.008M
March 31, 2023 -0.0253M
December 31, 2022 9.790M
September 30, 2022 -0.0247M
June 30, 2022 -0.0244M
March 31, 2022 -0.0371M
December 31, 2021 0.2823M
September 30, 2021 -0.2024M
June 30, 2021 0.00
March 31, 2021 -0.0046M
December 31, 2020 -0.0113M
September 30, 2020 -0.0778M
June 30, 2020 -0.0186M
March 31, 2020 0.00
Date Value
December 31, 2019 -0.3164M
September 30, 2019 -1.587M
June 30, 2019 30.64M
March 31, 2019 -1.00M
December 31, 2018 -2.470M
September 30, 2018 0.1565M
June 30, 2018 1.783M
March 31, 2018 -1.990M
December 31, 2017 -2.007M
September 30, 2017 -1.917M
June 30, 2017 -1.960M
March 31, 2017 -1.559M
December 31, 2016 14.38M
September 30, 2016 7.464M
June 30, 2016 -0.065M
March 31, 2016 -0.0065M
December 31, 2015 -0.0972M
September 30, 2015 29.64M
June 30, 2015 0.0409M
March 31, 2015 -0.6561M
December 31, 2014 29.21M
September 30, 2014 -0.1221M
June 30, 2014 -0.0132M
March 31, 2014 0.0314M
December 31, 2013 -0.006M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Decoy Therapeutics, Inc. 3.163M
ACADIA Pharmaceuticals, Inc. 10.49M
Alnylam Pharmaceuticals, Inc. 36.24M
Anika Therapeutics, Inc. -0.701M
Savara, Inc. 0.189M